Research programme: siRNA respiratory disorders therapeutics - GlaxoSmithKline/Sirna

Drug Profile

Research programme: siRNA respiratory disorders therapeutics - GlaxoSmithKline/Sirna

Latest Information Update: 23 Mar 2010

Price : $50

At a glance

  • Originator Sirna Therapeutics
  • Developer GlaxoSmithKline
  • Class
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Allergic rhinitis; Asthma; Respiratory syncytial virus infections; Respiratory tract disorders

Most Recent Events

  • 29 Jan 2008 Preclinical development is ongoing
  • 30 Dec 2006 Sirna Therapeutics has been acquired by Merck and Co
  • 12 May 2006 Preclinical trials in Respiratory syncytial virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top